An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery—the BUMPER study

BACKGROUND: Patients with melanoma brain metastasis (MBM) still carry a dismal prognosis. Preclinical data originated in xenograft models showed that buparlisib therapy was highly effective in therapy-naïve MBM. PATIENTS AND METHODS: In this open-label, phase II trial, we investigate the safety and...

Descripción completa

Detalles Bibliográficos
Autores principales: Amaral, Teresa, Niessner, Heike, Sinnberg, Tobias, Thomas, Ioannis, Meiwes, Andreas, Garbe, Claus, Garzarolli, Marlene, Rauschenberg, Ricarda, Eigentler, Thomas, Meier, Friedegund
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712798/
https://www.ncbi.nlm.nih.gov/pubmed/33305271
http://dx.doi.org/10.1093/noajnl/vdaa140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712798/
https://www.ncbi.nlm.nih.gov/pubmed/33305271
http://dx.doi.org/10.1093/noajnl/vdaa140

Ejemplares similares